title: Adjunctive topiramate in hospitalized children and adolescents with bipolar disorders.
abstract: OBJECTIVE
  The aim of this study was to assess topiramate as adjunctive treatment in children and adolescents hospitalized with bipolar disorders.
  
  
  METHODS
  Medical records of all children and adolescents with a Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV-TR) (APA, 2000) diagnosis of bipolar disorder, type I, hospitalized for an acute manic, mixed, or depressive episode, were reviewed. The primary outcome measure was the Clinical Global Impression-Severity (CGI-S) score.
  
  
  RESULTS
  Twenty-five (25) children and adolescents received topiramate, with a mean final dose of 126 mg/day (range, 25-350 mg). Overall CGI-S scores significantly improved from 5.3+/-1.0 to 3.5+/-0.7, and mania CGI-S scores decreased from 5.4+/-1.0 to 3.3+/-0.9. Sixteen (16) of 25 (64%) bipolar patients were classified as responders (defined by an endpoint overall CGI-I score of less than or equal to 2). No serious adverse events occurred during treatment. Of 25 patients evaluated, 1 (4%) experienced mild sedation while treated with topiramate.
  
  
  CONCLUSIONS
  Preliminary results of this retrospective chart review suggest that adjunctive topiramate may be associated with improvements in children and adolescents hospitalized for an acute manic, mixed, or depressive episode. Randomized and controlled trials with adjunctive topiramate in this population are needed to further explore this observation.
authors.affiliation: Cincinnati Children's Hospital Medical Center, Division of Child and Adolescent Psychiatry, and Department of Psychiatry, University of Cincinnati College of Medicine, Ohio 45267, USA. drew.barzman@cchmc.org
authors.forename: Drew H
authors.initials: DH
authors.lastname: Barzman
authors.forename: Melissa P
authors.initials: MP
authors.lastname: DelBello
authors.forename: Robert A
authors.initials: RA
authors.lastname: Kowatch
authors.forename: Juliet
authors.initials: J
authors.lastname: Warner
authors.forename: Dana
authors.initials: D
authors.lastname: Rofey
authors.forename: Kevin
authors.initials: K
authors.lastname: Stanford
authors.forename: Katherine
authors.initials: K
authors.lastname: Rappaport
authors.forename: John P
authors.initials: JP
authors.lastname: Daniels
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Strakowski
mesh_terms: D000293:Adolescent; D000927:Anticonvulsants / Q000008:administration & dosage* / Q000009:adverse effects; D018692:Antimanic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001714:Bipolar Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D005632:Fructose / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006760:Hospitalization; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D000077236:Topiramate; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D018692:Antimanic Agents; D000077236:Topiramate; D005632:Fructose